Jean-Marie Krzesinski

Jean-Marie Krzesinski

Auto-generated profile, based on publicly available information

Jean-Marie Krzesinski

Division of Nephrology, University of Liège Hospital (ULiège CHU), University of Liège, Belgium (J.H., J.-M.K., F.J.).

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2023 in Hypertension
Verified
Journal Article
Closed access
JHJustine Huart
Justine Huart
APAlexandre Persu
Alexandre Persu
JLJean-Philippe Lengelé
Jean-Philippe Lengelé
JKJean-Marie Krzesinski
Jean-Marie Krzesinski
FJFrançois Jouret
François Jouret
GSGeorge Stergiou
George Stergiou
The nondipping blood pressure (BP) pattern corresponds to a disruption in the circadian BP rhythm with an insufficient decrease in BP levels during nighttime sleep as observed using 24-hour ambulatory BP monitoring. Patients with nondipping BP pattern have poorer renal and cardiovascular outcomes, independent of their average 24-hour BP levels. The pathophysiology of nondipping BP is complex and involves numerous mechanisms: perturbations of (1) the circadian rhythm, (2) the autonomic nervous system, and (3) water and sodium regulation. This review provides an outline of the pathways potentially involved in the nondipping BP profile in different conditions. A recent hypothesis is also discussed involving the role of gut microbiota in the dipping/nondipping patterns, via the fecal diet-derived short chain fatty acids.

1 November 2019 in Journal of Renal Nutrition
Verified
Journal Article
Closed access
PDF file
PDPierre Delanaye
Pierre Delanaye
SBStanislas Bataille
Stanislas Bataille
KQKevin Quinonez
Kevin Quinonez
FBFanny Buckinx
Fanny Buckinx
XWXavier Warling
Xavier Warling
ECEtienne Cavalier
Etienne Cavalier

26 February 2021 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
RHRachel Hellemans
Rachel Hellemans
AKAnneke Kramer
Anneke Kramer
JMJohan De Meester
Johan De Meester
FCFrederic Collart
Frederic Collart
DKDirk Kuypers
Dirk Kuypers
KJKitty J Jager
Kitty J Jager
Background: Changes in recipient and donor factors have reopened the question of survival benefits of kidney transplantation versus dialysis. Methods: We analysed survival among 3808 adult Belgian patients waitlisted for a first deceased donor kidney transplant from 2000 to 2012. The primary outcome was mortality during the median waiting time plus 3 years of follow-up after transplantation or with continued dialysis. Outcomes were analysed separately for standard criteria donor (SCD) and expanded criteria donor (ECD) kidney transplants. We adjusted survival analyses for recipient age (20–44, 45–64 and ≥65 years), sex and diabetes as the primary renal disease. Results: Among patients ≥65 years of age, only SCD transplantation provided a significant survival benefit compared with dialysis, with a mortality of 16.3% [95% confidence interval (CI) 13.2–19.9] with SCD transplantation, 20.5% (95% CI 16.1–24.6) with ECD transplantation and 24.6% (95% CI 19.4–29.5) with continued dialysis. Relative mortality risk was increased in the first months after transplantation compared with dialysis, with equivalent risk levels reached earlier with SCD than ECD transplantation in all age groups. Conclusions: The results of this study suggest that older patients might gain a survival benefit with SCD transplantation versus dialysis, but any survival benefit with ECD transplantation versus dialysis may be small.

18 October 2017 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
PDPierre Delanaye
Pierre Delanaye
FPFrançois Paquot
François Paquot
ABAntoine Bouquegneau
Antoine Bouquegneau
FBFrank Blocki
Frank Blocki
JKJean-Marie Krzesinski
Jean-Marie Krzesinski
ECEtienne Cavalier
Etienne Cavalier
Sclerostin, a 22-kDa protein secreted by osteocytes, acts as a potent inhibitor of osteoblast activity. In chronic kidney disease (CKD), sclerostin is a putative driver of the bone–vascular axis. However, large discrepancies between sclerostin assays have been described. We compared four different assays [Biomedica (BM), TecoMedical (TE), R&D (RD) and MesoScaleDiscovery (MSD)] in an analytical study and addressed the question whether bioassay choice affects the correlation between circulating sclerostin and clinical and biochemical determinants. Circulating sclerostin levels were determined in 39 prevalent dialysis patients and 82 non-dialysis patients referred for glomerular filtration rate measurement. In the 82 non-dialysis patients, we observed large differences in median (interquartile range) sclerostin concentrations (in pg/mL): BM, 984 [interquartile range (IQR) 648]; TE, 629 (IQR 237); RD, 154 (IQR 84) and MSD, 36 (IQR 19). The concordance correlation coefficient between assays was poor (0.1–0.44). The same discrepancies were observed in dialysis patients. A significant negative rank correlation was found between glomerular filtration rate and sclerostin measured by BM and TE but not by MSD and RD. Associations between sclerostin and age, gender, weight or parathormone were also different according to the assay considered. Clinical inference relating sclerostin levels found in the general, CKD and dialysis populations is largely influenced by the assay used to measure this biomarker.

1 November 2012 in Transplantation Proceedings
Verified
Journal Article
Closed access
HDH. Le Dinh
H. Le Dinh
LWL. Weekers
L. Weekers
CBC. Bonvoisin
C. Bonvoisin
JKJ.M. Krzesinski
J.M. Krzesinski
JMJ. Monard
J. Monard
ODO. Detry
O. Detry

1 August 2006 in Clinical Nephrology
Verified
Journal Article
Closed access
PDP. Delanaye
P. Delanaye
ECEtienne Cavalier
Etienne Cavalier
JKJ.M. Krzesinski
J.M. Krzesinski
JCJ.-P. Chapelle
J.-P. Chapelle